ETC-1002: Completed Phase IIa enrollment

Esperion disclosed in its 2Q13 earnings that it completed enrollment of about 52 patients with hypercholesterolemia in the double-blind, placebo-controlled, U.S. Phase IIa ETC-1002-007 trial evaluatin...